510(k) Report

510(k) · Cleared

Cleared

RX Viatrac 18 Peripheral Dilatation Catheter, Otw Viatrac 18 Peripheral Dilatation Catheter

K993639510(k) TraditionalCleared Jan 27, 200091-day reviewClass II21 CFR 870.1250

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Guidant Corp. · LIT Catheter, Angioplasty, Peripheral, Transluminal

Cleared on Jan 27, 2000 as substantially equivalent to K983055 (Guidant Corp., 1998) and 1 other predicate after a 91-day review. Its family tree reaches back 2 generations to 1997.

Decided
Jan 27, 2000
Review
91 days
Class
Class II
Product code
LIT
Recalls
None
Predicates
2

Its longest line of descent runs back 2 generations to K970299 (1997). 3 ancestors in all. No later device cites it as a predicate yet.

  1. Root · 2 generations backK970299 Jupiter Pta Catheters (Various)Cordis Corp. · 1997
  2. 1 generation backK983055 RX Viatrac 14 Peripheral Dilatation Catheter, Model #'S 1003006-20…Guidant Corp. · 1998
  3. This deviceK993639 RX Viatrac 18 Peripheral Dilatation Catheter, Otw Viatrac 18…Guidant Corp. · 2000
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K970299Jupiter Pta Catheters (Various)Cordis Corp.1997—
−1K983055RX Viatrac 14 Peripheral Dilatation Catheter, Model #'S 1003006-20…Guidant Corp.1998—
0 (this device)K993639RX Viatrac 18 Peripheral Dilatation Catheter, Otw Viatrac 18 Peripheral…Guidant Corp.2000—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199710
FIG. 1 — Lineage of K993639, 1997–2000Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LIT? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LIT device

  1. #1 K241040 Amethyst HP PTA OTW 0.035 Catheterscore 13.9 · 9 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K983055RX Viatrac 14 Peripheral Dilatation Catheter, Model #'S 1003006-20, 1003007-20…
Summary page 1
…Device Common Name: Percutaneous Transluminal Angioplasty Catheter Device Classification Name: LIT Predicate Devices: = RX VIATRAC™ 14 Peripheral Dilatation Catheter (K983055) Cordis OPTA 5™ PTA Catheter (K972825) Device Description: The RX VIATRAC™ 18 and the OTW VIATRAC™ 18 Peripheral Dilatation Cat…
Guidant Corp.1998—
*K972825OPTA5 Pta Balloon Catheter, Powerflex Pta Balloon Catheter, Ultra-Thin Diamond Balloon…
Summary page 1
…sluminal Angioplasty Catheter Device Classification Name: LIT Predicate Devices: = RX VIATRAC™ 14 Peripheral Dilatation Catheter (K983055) Cordis OPTA 5™ PTA Catheter (K972825) Device Description: The RX VIATRAC™ 18 and the OTW VIATRAC™ 18 Peripheral Dilatation Catheters were developed in parallel as t…
Cordis Corp.1997—

Also cleared against K983055: 2 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 3 years and passes through 2 companies; a new generation was cleared every 1.7 years on median.
  • None of the 3 ancestors has a recall.
  • 2 other devices also cite its predicate K983055.

How does its category compare?

All LIT devices

LIT Catheter, Angioplasty, Peripheral, Transluminal: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · LIT

3in 2025

2007: 62008: 82009: 72010: 132011: 102012: 192013: 142014: 122015: 192016: 112017: 92018: 62019: 42020: 92021: 42022: 82023: 62024: 62025: 32026 (partial year): 4
2007high 19 (2012) · low 3 (2025)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LIT

90in 2025

2007: 64 days median2008: 53 days median2009: 29 days median2010: 78 days median2011: 82 days median2012: 29 days median2013: 79 days median2014: 90 days median2015: 112 days median2016: 116 days median2017: 57 days median2018: 118 days median2019: 40 days median2020: 125 days median2021: 61 days median2022: 122 days median2023: 167 days median2024: 43 days median2025: 90 days median2026 (partial year): 205 days median
2007high 205 (2026) · low 29 (2009)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · LIT

1in 2025

2009: 22010: 12013: 2, 2 Class I2014: 32016: 12018: 22019: 32021: 12024: 22025: 1
2007high 3 (2014) · low 0 (2007)2026

Class I (2 since 2007) Class II/III not classified

Adverse event reports per year · LIT

2,073in 2025

2007: 5772008: 5132009: 6232010: 8092011: 8572012: 1,2772013: 1,2422014: 1,1782015: 1,2792016: 1,5292017: 2,0812018: 2,1882019: 2,4052020: 2,4432021: 2,4922022: 2,1552023: 1,8072024: 1,9132025: 2,073
2007high 2,492 (2021) · low 513 (2008)2025

MAUDE reports naming product code LIT, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20076640577
20088530513
20097292623
201013781809
201110820857
2012192901,277
201314792 (2)1,242
2014129031,178
20151911201,279
20161111611,529
201795702,081
2018611822,188
201944032,405
2020912502,443
202146112,492
2022812202,155
2023616701,807
202464321,913
202539012,073
202642050—

What is it indicated for?

The RX VIATRAC™ 18 Peripheral Dilatation Catheter is intended: To dilate stenoses in the peripheral arteries (iliac, femoral, ilio-femoral, popliteal, infra popliteal, renal arteries) For the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. For post deployment optimization of the 28 mm GUIDANT MEGALINK™ Biliary Stent (6.0 to 10.0 mm diameters). The OTW VIATRAC™ 18 Peripheral Dilatation Catheter is intended: To…

Read the full statement (108 words)

The RX VIATRAC™ 18 Peripheral Dilatation Catheter is intended:

To dilate stenoses in the peripheral arteries (iliac, femoral, ilio-femoral, popliteal, infra popliteal, renal arteries)

For the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

For post deployment optimization of the 28 mm GUIDANT MEGALINK™ Biliary Stent (6.0 to 10.0 mm diameters).

The OTW VIATRAC™ 18 Peripheral Dilatation Catheter is intended:

To dilate stenoses in the peripheral arteries (iliac, femoral, ilio-femoral, popliteal, infra popliteal, renal arteries)

For the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

For post deployment optimization of the 28 mm GUIDANT MEGALINK™ Biliary Stent (6.0 to 10.0 mm diameters).

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K993639: RX Viatrac 18 Peripheral Dilatation Catheter, Otw Viatrac 18 Peripheral Dilatation Catheter.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K993639

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026